Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Ovarian Cancer
Has your preferred adjuvant treatment for IC mucinous ovarian cancer changed in response to the platinum chemotherapy shortage?
Answer from: at Community Practice
We previously offered observation to Stage IC low grade mucinous ovarian cancer so this has not impacted our decision.
Sign In
or
Register
to read more
17555
Related Questions
How does your management and counseling of a patient with ovarian cancer change when they have significant persistent disease after neoadjuvant chemotherapy?
How do you manage patients with germline BRCA mutations who have STIC lesions found at the time of risk-reducing BSO?
Do you believe the collective data support neoadjuvant chemotherapy or primary debulking surgery for patients with advanced ovarian cancer?
How do you factor a decreasing but persistently elevated CA-125 into your decision regarding whether to proceed with interval cytoreductive surgery for PAX8+ high-grade serous cancer s/p neoadjuvant chemotherapy with minimal disease on imaging?
How do you logistically incorporate a "scope and score" of a patient with newly diagnosed advanced ovarian cancer into a busy OR schedule?
Have you had patients who wish to take ivermectin and/or fenbendazole as adjunct treatments for gynecologic cancers, and if so, how have you handled this?
For an elderly woman with a platinum-resistant recurrence of a high-grade serous ovarian cancer who has been rendered NED surgically, is observation a reasonable approach?
Would you consider adding immunotherapy to adjuvant chemotherapy in a patient with incompletely staged, high-grade, MSI-H, POLE-mutated endometrioid carcinoma of the ovary with ultra-high tumor mutation burden on NGS?
What does bevacizumab contribute in metastatic cervical cancer when used in combination with a platinum doublet + pembrolizumab?
How do you decide until what age to offer ovarian preservation for patients with biopsy-proven grade 1 or grade 2 endometrial cancer without evidence of metastatic disease on imaging or at the time of surgery?